Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
GliomaLow-grade GliomaAstrocytoma
Interventions
DRUG

everolimus

Trial Locations (10)

10016

New York University, New York

10174

Memorial Sloan-Kettering Cancer Institute, New York

21231

John Hopkins Medical Center, Baltimore

30322

Children's Healthcare of Atlanta, Atlanta

32610

University of Florida College of Medicine, Gainesville

80045

The Children's Hospital, Denver

85016

Phoenix Children's Hospital Center for Cancer and Blood Disorders, Phoenix

97239

Doernbecher Children's Hospital Oregon Health & Science University, Portland

98109

Seattle Cancer Care Alliance, Seattle

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Pediatric Oncology Experimental Therapeutics Investigators' Consortium

UNKNOWN

lead

Dana-Farber Cancer Institute

OTHER

NCT00782626 - Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | Biotech Hunter | Biotech Hunter